The H100: How a Desktop HPLC Lab Instrument Commoditizes Chronic Disease Screening

H100 Hemoglobin Analyzer (HbA1c HPLC System) – High-Precision Diabetes & Thalassemia Testing

The H100 is a fully automated HPLC hemoglobin analyzer built to process two of the most common blood-panel tests—HbA1c for diabetes and variant detection for β-thalassemia—on a single platform. It completes an HbA1c run in 96 seconds and holds up to 110 samples in its autoloader, which makes it a fit for high-throughput hospital labs and regional diagnostic hubs.

Switching between test modes is a one-click operation. The instrument automates sample mixing, variant flagging, and data storage for 20,000 results. Certification against NGSP and IFCC standards means results are traceable to international diabetes-management protocols, removing the recalibration friction that often slows adoption.

What this reveals about China’s diagnostic-equipment supply chain is the degree of vertical integration now possible. HPLC columns, pumps, and detectors that once required German or Japanese subsystems are increasingly sourced domestically, compressing both cost and lead time. A device like the H100 can be deployed in county-level hospitals without relying on foreign service contracts.

For procurement officers, the practical calculus is straightforward: one machine replaces two dedicated analyzers, reduces per-test reagent waste, and cuts operator training to minimum via a Linux-based touch interface. In markets where lab technicians are scarce, that is non-trivial.

The H100 does not solve the underlying epidemiology. It solves the throughput bottleneck that stands between epidemiology and action.

Why it matters:
By bundling dual-disease screening into a single HPLC platform, the H100 lowers the capital barrier for labs in emerging health systems, accelerating early diagnosis at the point where infrastructure is thinnest.

View Product →